Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin-aldosterone system

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 11, Issue 2, 2010, Pages 124-126

  Yoshimura, Michihiro ^a   Kawai, Makoto ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ARB; Circulating RAAS; Hydrochlorothiazide; Sodium; Tissue RAAS

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; GUANOSINE TRIPHOSPHATASE; MINERALOCORTICOID RECEPTOR; RAC1 PROTEIN; RENIN; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HEART; NONHUMAN; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR SYSTEM; DRUG THERAPY, COMBINATION; HUMANS; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 77953205564     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320310361832     Document Type: Review

References (24)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
2. Psaty BM, Lumley T., Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA 2003; 289: 2534-2544.
3. Julius S., Kjeldsen SE, Weber M. et al.; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
4. Lithell H., Hansson L., Skoog I. et al.; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
5. Dahlof B., Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
6. Palatini P., Malacco E., Di SS et al. Trough peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Eur J Clin Pharmacol 2002; 57: 765-770.
7. Bangalore S., Kamalakkannan G., Parkar S., Messerli F. Fixed-dose combinations improve medication compliance: a meta analysis. Am J Med 2007; 120: 713-719.
8. Law MR, Wald NJ, Morris JK, Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-1434.
9. Dzau VJ Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
10. Navar LG, Mitchell KD, Harrison-Bernard LM et al. Intrarenal angiotensin II levels in normal and hypertensive states. J Renin Angiotensin Aldosterone Syst 2001; 2: S176-84.
11. Hokimoto S., Yasue H., Fujimoto K. et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94: 1513-1518.
12. Liang B., Leenen FH Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats. Br J Pharmacol 2007; 152: 903-914.
13. Danser AHJ, van Kats JP, Admiraal PJJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48.
14. de Lannoy LM, Danser AHJ, Bouhuizen AMB, et al. Localization and production of angiotensin II in the isolated perfused rat heart. Hypertension 1998; 31: 1111-1117.
15. Mizuno Y., Yoshimura M., Yasue H. et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-77.
16. Yamamoto N., Yasue H., Mizuno Y. et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002; 39: 958-962.
17. Takeda Y., Yoneda T., Demura M. et al. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001; 19: 635-639.
18. Yamamuro M., Yoshimura M., Nakayama M. et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 2006; 147: 1314-1321.
19. Gomez-Sanchez EP, Ahmad N., Romero DG, Gomez-Sanchez CE Origin of Aldosterone in the Rat Heart. Endocrinology 2004; 145: 4796-4802.
20. Harada E., Yoshimura M., Yasue H. et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137-139.
21. Yamamuro M., Yoshimura M., Nakayama M. et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocyocytes. Circ J 2008; 72: 1346-1350.
22. Barauna VG, Magalhaes FC, Krieger JE et al. AT1 receptor participates in the cardiac hypertrophy induced by resistance training in rats. Am J Physiol Regul Integr Comp Physiol 2008; 295: R381-7.
23. Sechi LA, Griffin CA, Giacchetti G. et al. Tissue-specific regulation of type 1 angiotensin II receptor mRNA levels in the rat. Hypertension 1996; 28: 403-408.
24. Shibata S., Nagase M., Yoshida S. et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008; 14: 1370-1376.